VCU Massey Cancer Center will serve as the National Program Office for the Alliance for Equity in Cancer Care, an initiative funded by the Merck Foundation and designed to make cancer care more equitable in the U.S. by helping cancer patients living in underserved communities receive timely access to high-quality, culturally responsive care.
Sunny R. K. Singh has joined the University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute as a hematologist/oncologist and director of the UAMS Baptist Health Cancer Center in North Little Rock.
Jonathan Laryea, chief of the Division of Colorectal Surgery in the Department of Surgery and medical director of cancer services at UAMS Winthrop P. Rockefeller Cancer Institute was named the Nolie and Norma Mumey Endowed Chair in Surgery in a Sept. 7 ceremony.
The University of Arkansas for Medical Sciences’ Fay W. Boozman College of Public Health will conduct trainings for faculty and students in health care programs offered at colleges or universities in Arkansas to address unconscious biases in health care. The trainings are supported by a $600,000 grant from the CDC.
NCI has awarded a five-year, $13.3 million grant to a collaborative study on sequential combinations of targeted inhibitors and immunotherapies against cancer.
Kevin Campbell was named chief information officer of the Translational Genomics Research Institute, part of City of Hope.
City of Hope has received a $25 million gift from Julia and George Argyros, longtime City of Hope supporters.
Lynda Carter Altman and Robert AltmanThe Translational Genomics Research Institute, part of City of Hope, formed a partnership with actress, singer-songwriter, and advocate, Lynda Carter Altman, to accelerate diagnostics and treatments, including precision medicine approaches, for secondary acute myeloid leukemia.
Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 grant from Stand Up To Cancer to explore therapeutic approaches to lung tumors with mutations in the KRAS gene, an undertaking that could have a significant impact for a large population of cancer patients who currently lack effective treatment options.
Stand Up To Cancer formed three teams investigating treatments for Non-Small Cell Lung Cancer and Ewing sarcoma, including a Lung Cancer Health Equity SU2C Catalyst Research Team with support from Bristol Myers Squibb and two SU2C Catalyst Research Teams with support from Jazz Pharmaceuticals.
